Cosmo Pharmaceuticals N.V. (LON:0RGI)

Market Cap	968.91M
Revenue (ttm)	156.24M
Net Income (ttm)	51.42M
Shares Out	n/a
EPS (ttm)	3.14
PE Ratio	18.84
Forward PE	31.46
Dividend	1.73 (2.57%)
Ex-Dividend Date	Jun 4, 2025

Volume	462
Average Volume	3,185
Open	67.40
Previous Close	67.50
Day's Range	66.50 - 67.55
52-Week Range	41.65 - 70.05
Beta	1.28
RSI	38.97
Earnings Date	Oct 31, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RGI

Financial Performance

Financial numbers in EUR